DyeVert™ PLUS

Taking Kidney Care to Heart

Revolutionary contrast reduction,
uncompromised imaging.

Have a Heart, Be Kind to Kidneys™

At Osprey Medical, our mission is to improve outcomes in patients with Chronic Kidney Disease by reducing contrast induced Acute Kidney Injury (AKI) and lowering hospital costs. Osprey’s proprietary technologies reduce the amount of contrast (dye) injected into patients during heart catheterization procedures without compromising X-ray image quality for the physician.

Learn more

We are Osprey Medical

Our vision is to make angiography safer for CKD patients.

Kidney Care is about reducing AKI in the Cath Lab

Dr. Anand Prasad shares his expertise in treating CKD patients in the Cath Lab.

Uncompromised Dye Reduction

The only FDA indicated technology for reducing dye dosage to patients

Watch the video

US Government to Transform Kidney Care

July 12, 2019

Osprey Medical (ASX: OSP) today announces its response to the US President signing an Executive Order aimed at transforming kidney care for more than 37 million Americans with some form of kidney disease. The initiative seeks to prevent kidney failure through better diagnosis, treatment and preventative care.

AKI Burden of Illness Data Presented at Premier® Breakthroughs Conference

June 21, 2019

Osprey Medical (ASX: OSP) today announces that Dr Anand Prasad, M.D., Director of the Cardiac Catheterization Laboratory at University Health System and Associate Professor of Medicine at UT Health Science Centre at San Antonio, Texas presented the Acute Kidney Injury (AKI) Burden of Illness Study1 at the Premier Breakthroughs 2019 Conference and Exhibition in Nashville, Tennessee on behalf of the study investigators.

Photo credit (Kidney Care): Blausen.com staff (2014). “Medical gallery of Blausen Medical 2014“. WikiJournal of Medicine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436.